LEO Pharma's Delgocitinib NDA219155 Receives AP Status from FDA
LEO Pharma's supplemental NDA for Delgocitinib has been granted an Approval Pending (AP) status by the FDA.
Company
Pharmaceutical intelligence for LEO Pharma with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.